Page 3 - V Imaging News Today

Artificial intelligence has the potential to add value to cardiac imaging at every step of the patient journey, the AHA said in a new scientific statement.

New observational data suggested direct oral anticoagulants may be the optimal antithrombotic regime after transcatheter mitral valve replacement; randomized trials were needed.

The update includes new recommendations on temperature management and percutaneous coronary angiography in adults suffering cardiac arrest.

Preliminary results of the pivotal phase 3 trial show benefit of the cardiac myosin inhibitor, aficamten, in obstructive hypertrophic cardiomyopathy.

The Barostim neuromodulation system is now indicated in NYHA class III or class II HF despite guideline-directed medical therapies, with LVEF ≤ 35% and NT-proBNP < 1600 pg/mL.

The emergence of new medicinal treatments may have changed the risk-benefit ratio of routine ICD implantation in patients with a severely abnormal LVEF after a heart attack.

Clinicians question the group's methodology, but the Lown Institute, that produced the report, stands by its methods and conclusions.

Patients with transthyretin amyloid cardiomyopathy taking tafamidis have less worsening of cardiac function than those on placebo, post hoc analysis of randomized results suggests.

The SELECT trial catapulted GLP-1 RAs into the forefront of CVD prevention, but cardiologists are making their own decisions about whether and how they might integrate these agents into practice.

Transcatheter tricuspid repair reduced valve regurgitation and improved quality of life at 1 year even for the sickest patients, but mortality remained high, new analysis of TRILUMINATE trial shows.